Physician profile
Steven C Eidt
NPI 1275561557
$6,850.21
in general payments reported to CMS, 2019-2025
23 companies · $787 in 2025
The $787 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $900 · 2021: $1,272 · 2022: $1,464 · 2023: $1,054 · 2024: $570 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,963.42 | 2021-2025 | |
| Alcon Vision LLC | $1,254.30 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Argos |
| Novartis Pharmaceuticals Corporation | $786.56 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $311.21 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Johnson & Johnson Surgical Vision, INC. | $296.92 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $282.21 | 2019-2025 | Cequa |
| Allergan, INC. | $280.27 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $247.53 | 2020-2021 | |
| Oyster Point Pharma, INC. | $240.15 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Ocular Therapeutix, INC. | $200.00 | 2019 | |
| Harrow Eye, LLC | $171.42 | 2024-2025 | Vevye |
| Dompe US, INC. | $119.90 | 2019 | |
| Rxsight INC | $100.44 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.19 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $96.21 | 2024-2025 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $87.02 | 2023-2025 | Iyuzeh |
| Astellas Pharma US INC | $69.47 | 2024 | Izervay |
| Biotissue Holdings INC. | $69.02 | 2019-2021 | |
| New World Medical,INC. | $58.55 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $43.32 | 2024 | |
| Eyevance Pharmaceuticals LLC | $31.89 | 2020-2021 | |
| Shire North American Group INC | $23.00 | 2019 | |
| Amgen INC. | $17.21 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.